Eagle’s Eye View: Your Weekly CV Update from ACC.org (Week of Oct. 31)

In this week’s View, Dr. Eagle discusses a secondary analysis of the REPRISE III randomized clinical trial on long-term outcomes of transcatheter aortic valve replacement with the Lotus valve vs the CoreValve/EvolutR, then looks at iron deficiency and cardiovascular disease. Finally, Dr. Eagle explores the association of race and ethnicity with oral anticoagulation and associated outcomes in patients with atrial fibrillation.

Clinical Topics: Arrhythmias and Clinical EP, Cardiac Surgery, Diabetes and Cardiometabolic Disease, Heart Failure and Cardiomyopathies, Invasive Cardiovascular Angiography and Intervention, Noninvasive Imaging, Prevention, Pulmonary Hypertension and Venous Thromboembolism, Valvular Heart Disease, Atherosclerotic Disease (CAD/PAD), Atrial Fibrillation/Supraventricular Arrhythmias, Aortic Surgery, Cardiac Surgery and Arrhythmias, Cardiac Surgery and Heart Failure, Cardiac Surgery and VHD, Acute Heart Failure, Pulmonary Hypertension, Interventions and Coronary Artery Disease, Interventions and Imaging, Interventions and Structural Heart Disease, Interventions and Vascular Medicine, Echocardiography/Ultrasound, Hypertension

Keywords: Transcatheter Aortic Valve Replacement, Aortic Valve, Aortic Valve Stenosis, Hemodynamics, Echocardiography, Pacemaker, Artificial, Thrombosis, Risk Factors, Stroke, Cardiovascular Diseases, Fibrinolytic Agents, Hepcidins, Iron, Dietary, Heart Failure, Atrial Fibrillation, Coronary Artery Disease, Hypertension, Pulmonary, Inflammation, Cerebrovascular Disorders, Heart Valve Diseases, Kidney Diseases, Atherosclerosis, EaglesEyeView

< Back to Listings